-
Marchés
athexgroup.grAthens Exchange GroupLire la suiteTogether for a unified, stronger European capital market.
-
Actions
Sustainable finance2025 Euronext ESG Trends ReportLire la suiteA data-driven snapshot of how Euronext-listed companies are advancing their Environmental, Social and Governance (ESG) practices.
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLire la suiteThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
ETF
The European market place for ETFsEuronext ETF EuropeLire la suiteInvestors benefit from a centralised market place that will not only bring transparency but also better pricing due to the grouping of liquidity.
- Fonds
-
Obligations
European Defence BondsGroupe BPCE lists the first bondLire la suiteFirst financial institution in Europe to issue a bond dedicated to the defence sector
- Produits Structurés
-
Dérivés
Where European Government Bonds Meet the FutureTrade Mini Bond FuturesLire la suiteTrade mini bond futures on main European government bonds
-
Matières Premières
- Vue d'ensemble
- Cours MATIF
- Power Derivatives
- Milling Wheat derivatives
- Corn derivatives
- Spread contracts
- Rapeseed derivatives
- Durum Wheat derivatives
- Dairy derivatives
- Salmon derivatives
- Container Freight Futures
- Règlement livraison
- Spécifications et dispositions
- Commitments of Traders (CoT) report
- Commodity brokers
Building a sustainable and liquid power derivatives market.Euronext Nord Pool Power FuturesLire la suiteEuronext and Nord Pool, the European power exchange, announced the launch of a dedicated Nordic and Baltic power futures market.
-
Ressources
Designed to help students navigate the complexities of financial marketsEuronext Trading gameLire la suiteJoin the Euronext Trading Game and step into capital markets. Learn from today’s leaders, explore sustainable opportunities, and trade with confidence.
British cancer drug developer Ellipses Pharma considers London listing (November 18)
(Corrects ninth bullet to say "An Abu Dhabi investment company" not "Waleed al-Mokarrab al-Muhairi" owns 45% of Ellipses in November 18 story)
Nov 18 (Reuters) - British cancer drug developer Ellipses Pharma on Wednesday said it was exploring a London listing through a deal with special purpose acquisition company Wolfram Resources.
• The company is targeting a valuation of between £450 million and £500 million ($594 million-$660 million), the Times reported on Sunday
• Established in 2017, Ellipses Pharma's pipeline includes trials for drugs to treat non-small cell lung cancer and breast cancer
• The London listing would follow a reverse takeover by shell company Wolfram Resources
• Terms of the deal are yet to be agreed and have not been disclosed
• The floatation will provide a boost to the UK stock market, which has seen an exodus from companies eyeing higher valuations in markets like the United States
• Ellipses Pharma is targeting completing the transaction by early 2027
• It expects an equity fundraise in conjunction with the deal
• Listing through a reverse takeover process will enable the company to raise additional capital from public company investors, founder and chair Chris Evans said
• An Abu Dhabi investment company owns about 45% of Ellipses, the Times report said
• The report also named celebrity investors such as composer Andrew Lloyd Webber, Rolling Stones guitarist Ronnie Wood and comedian Jimmy Carr
• The company did not immediately comment on valuation and investors
(Reporting by Simone Lobo in Bengaluru; Editing by Nivedita Bhattacharjee)
Find it fast
Looking for more insights? Explore our other news sections for updates on sustainable finance, companies and financial education